What is LBRX's cash & equivalents?

LBRX (LBRX) reported cash & equivalents of $320.68M in Q1 2026.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

LBRX LBRX Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers SquibbBMY

$9.57B-12.0%

AlkermesALKS

$351.55M-12.1%

MapLight Therapeutics, Inc. MPLT

$55.71M—

Alto NeuroscienceANRO

$264.26M+63.9%

Zevra Therapeutics, Inc.ZVRA

$95.6M+156%

Acadia PharmaceuticalsACAD

$282.21M+29.6%

Other financials

Income statement

See full

Net income-$19.1M-259%

EPS (diluted)-$0.67+95.5%

Balance sheet

See full

Total debt$3.5M—

Total equity$378.7M+481%

Total assets$393.5M—

Cash flow

See full

Operating cash flow-$23.3M-187%

CapEx$32.0K+52.4%

Free cash flow-$23.3M-186%

Valuation

See full

Market cap$874.06M+159%

Enterprise value$556.86M—

Returns & leverage

See full

Return on equity-27.9%—

Debt / equity0×—

Current ratio35.7×—

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is LBRX's cash & equivalents?: LBRX (LBRX) reported cash & equivalents of $320.68M in Q1 2026.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.